Gold Prices Rise as Oil Slump Eases Fed Rate Hike Fears 
Anthropic’s Claude Discovers CRISPR-Like Enzyme System 
U.S. 10-Year Treasury Yield Hits 2007 High as Fed Rate Hike Bets Rise 
fnny Beta Launches With a Simple Idea: Find an Event, Show Up, Get Rewarded 
China Vanke Shares Jump as Beijing Moves to Ease Debt Pressure 
OpenAI Urges US-Led Global Standards for Frontier AI 
Asian Stocks Mixed Ahead of Trump-Xi Meeting 
European Stocks Slip as Iran Tensions Offset Strong Eurozone Data 
Asian Currencies Muted as Dollar Firms Ahead of Trump-Xi Summit 
Trump Bans CNN, MS NOW and Politico From White House 
Russian Envoy Dmitriev Heads to US for Ukraine Talks 
Oil Prices Surge as U.S.-Iran Diplomacy Hopes Fade 
Petrobras Joins Brazil Diesel Subsidy Program 
US, Japan and South Korea Back Taiwan Ahead of Trump-Xi Summit 
RBA Says ASX Still Falls Short on Governance and Risk Controls 
Oil Prices Rise as U.S.-Iran Talks Fuel Diplomacy Hopes 
Oil Prices Ease as Iran Tensions Clash With Diplomacy Hopes 
Add as a preferred source on Google
Samsung Biologics signed a contract manufacturing organization (CMO) deal with GreenLight Biosciences to produce COVID-19 vaccines for poor nations, particularly in Africa. The South Korean pharma company revealed its new partnership agreement with the Boston-based biotech firm on Thursday, Nov. 25.
Samsung Biologics and GreenLight Biosciences’ goal is to bring vaccines to everyone as they want to have a world that has the ability to produce sufficient messenger RNA vaccine doses for billions of people per year.
As per The Korea Herald, the agreement between the companies stated that the Korean pharma company would produce drug materials for GreenLight’s COVID-19 vaccine candidate. The two firms also agreed to scale up research and manufacturing efforts so they can be able to allocate more coronavirus vaccines for underdeveloped countries.
Samsung’s pharma unit added that it would be expanding its production plant in Songdo, Incheon, by building new facilities on the site. The constructions are expected to be completed by April next year.
“We are delighted to partner with GreenLight to leverage our expertise in manufacturing a messenger RNA COVID-19 vaccine candidate to better serve patients in lower income countries,” Samsung Biologics chief executive officer, John Rim, said in a press release. “This collaboration demonstrates a major milestone for Samsung Biologics as we will commence our expanded capabilities and operations to provide one-stop end-to-end messenger RNA production from Drug Substance (DS) to Aseptic Fill Finish (DP) to commercial release, all from a single site.”
Meanwhile, GreenLight Biosciences is also reported to be in the last stage of finalizing its partnership deal with a local partner in Africa. This is a separate agreement with Samsung Biologics, and after the contracts are sealed, the American biotech company is planning to start the phase 1 clinical trials for its vaccine candidate as early as the first quarter of 2022, as per Korea Joongang Daily.
Samsung Biologics and GreenLight Biosciences are producing COVID-19 vaccines using mRNA or messenger ribonucleic acid. This is the same type applied to Pfizer and Moderna vaccines.
Finally, Andrey Zarur, GreenLight CEO, said they are happy to join forces with Samsung to make messenger RNA for their Covid vaccine trial as there is an urgent need to develop vaccines for the whole world.
